The study evaluated CD19 CAR T-cell therapy in patients with refractory autoimmune hemolytic anemia (rAIHA) who had failed at least three lines of therapy; 8 patients were enrolled in the compassionate-use program (n=5) and in a phase I clinical trial (NCT06231368, n=3).[1] Patients received a single infusion of autologous CD19 CAR T-cells at a dose of 1×10^6/kg.[1] Safety included assessment of cytokine release syndrome (CRS), neurotoxicity (ICANS), and other toxicities according to CTCAE version 5.0; one patient had CRS grade 1 and one ICANS grade 1, with no hospitalizations for severe infections.[1] Of the 7 evaluable patients, all achieved complete remission (CR), a CR rate of 100%; one relapse occurred after 6.8 months with a relapse-free duration (DFR) of 6.3 months.[1] CAR T-cell levels increased rapidly, with a peak at a median of 10 days (range, 7-11 days) and a median concentration of 118.8 cells/µl (range, 44.9-244.6).[1] The therapy induced rapid remission, unprecedented DFR, and a favorable safety profile in patients with rAIHA.[1]